These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20231907)

  • 1. Two-sample tests of area-under-the-curve in the presence of missing data.
    Spritzler J; DeGruttola VG; Pei L
    Int J Biostat; 2008 Jan; 4(1):Article 1. PubMed ID: 20231907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for associations with missing high-dimensional categorical covariates.
    Schumi J; DiRienzo AG; DeGruttola V
    Int J Biostat; 2008 Sep; 4(1):Article 18. PubMed ID: 20231909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian framework for intent-to-treat analysis with missing data.
    Kleinman KP; Ibrahim JG; Laird NM
    Biometrics; 1998 Mar; 54(1):265-78. PubMed ID: 9544521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is using multiple imputation better than complete case analysis for estimating a prevalence (risk) difference in randomized controlled trials when binary outcome observations are missing?
    Mukaka M; White SA; Terlouw DJ; Mwapasa V; Kalilani-Phiri L; Faragher EB
    Trials; 2016 Jul; 17():341. PubMed ID: 27450066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217.
    Messer K; Vaida F; Hogan C
    Contemp Clin Trials; 2006 Dec; 27(6):506-17. PubMed ID: 16962381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratified tests, stratified slopes, and random effects models for clinical trials with missing data.
    Dawson JD; Han SH
    J Biopharm Stat; 2000 Nov; 10(4):447-55. PubMed ID: 11104386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
    Hou Y; Ding V; Li K; Zhou XH
    J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.
    Scharfstein DO; Daniels MJ; Robins JM
    Biostatistics; 2003 Oct; 4(4):495-512. PubMed ID: 14557107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighted estimation of the accelerated failure time model in the presence of dependent censoring.
    Cho Y; Ghosh D
    PLoS One; 2015; 10(4):e0124381. PubMed ID: 25909753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missing data mechanisms in a dose-finding adaptive trial.
    Liu K; Entsuah R
    J Biopharm Stat; 2012; 22(2):329-37. PubMed ID: 22251177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics.
    Le Corfec E; Chevret S; Costagliola D
    Stat Med; 1999 Jul; 18(14):1803-17; discussion 1819. PubMed ID: 10407251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical power for distribution-free tests of incomplete longitudinal data with applications to AIDS clinical trials.
    Kuhn AM; DeMasi RA
    J Biopharm Stat; 1999 Aug; 9(3):401-16. PubMed ID: 10473028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
    Siddiqui O; Hung HM; O'Neill R
    J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demystifying optimal dynamic treatment regimes.
    Moodie EE; Richardson TS; Stephens DA
    Biometrics; 2007 Jun; 63(2):447-55. PubMed ID: 17688497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Likelihood-based inferences about the mean area under a longitudinal curve in the presence of observations subject to limits of detection.
    Chandrasekhar R; Shi Y; Hutson AD; Wilding GE
    Pharm Stat; 2015; 14(3):252-61. PubMed ID: 25832442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jointly Modeling Event Time and Skewed-Longitudinal Data with Missing Response and Mismeasured Covariate for AIDS Studies.
    Huang Y; Yan C; Xing D; Zhang N; Chen H
    J Biopharm Stat; 2015; 25(4):670-94. PubMed ID: 24905593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of missing data in a generalized integer-valued autoregression model for count data.
    Alosh M
    J Biopharm Stat; 2009 Nov; 19(6):1039-54. PubMed ID: 20183463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.
    Wu H; Ding AA
    Biometrics; 1999 Jun; 55(2):410-8. PubMed ID: 11318194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.